Innovative financing instruments for global health 2002–15: a systematic analysis

Rifat Atun, Sachin Silva, Felicia M. Knaul

Research output: Contribution to journalComment/debatepeer-review

25 Scopus citations


Development assistance for health (DAH), the value of which peaked in 2013 and fell in 2015, is unlikely to rise substantially in the near future, increasing reliance on domestic and innovative financing sources to sustain health programmes in low-income and middle-income countries. We examined innovative financing instruments (IFIs)—financing schemes that generate and mobilise funds—to estimate the quantum of financing mobilised from 2002 to 2015. We identified ten IFIs, which mobilised US$8·9 billion (2·3% of overall DAH) in 2002–15. The funds generated by IFIs were channelled mostly through GAVI and the Global Fund, and used for programmes for new and underused vaccines, HIV/AIDS, malaria, tuberculosis, and maternal and child health. Vaccination programmes received the largest amount of funding ($2·6 billion), followed by HIV/AIDS ($1080·7 million) and malaria ($1028·9 million), with no discernible funding targeted to non-communicable diseases.

Original languageEnglish (US)
Pages (from-to)e720-e726
JournalThe Lancet Global Health
Issue number7
StatePublished - Jul 2017

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Innovative financing instruments for global health 2002–15: a systematic analysis'. Together they form a unique fingerprint.

Cite this